Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

References

• Fisher R I, Gaynor E R, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Velasquez W S, McLaughlin P, Tucker S, et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Jermann M, Jost L M, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15: 511–516
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar
• El Gnaoui T, Dupuis J, Belhadj K, Jais J P, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007; 18: 1363–1368
   PubMed Web of Science ®Google Scholar
• Hochster H S, Kim K M, Green M D, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10: 28–32
   PubMed Web of Science ®Google Scholar
• Redman J R, Cabanillas F, Velasquez W S, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003; 77: 164–170
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski J Z. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006; 107: 1542–1550
   PubMed Web of Science ®Google Scholar
• Decaudin D, Bosq J, Tertian G, et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998; 16: 579–583
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167–1173
   PubMed Web of Science ®Google Scholar
• Uy G L, Tomasson M H, Ruddell A, DiPersio J F, Vij R. The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma. Haematologica 2006; 91: 1581–1582
   PubMed Web of Science ®Google Scholar
• Gandhi V, Plunkett W, Bonate P L, et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 2006; 12: 4011–4017
   PubMed Web of Science ®Google Scholar
• Jeha S, Gandhi V, Chan K W, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784–789
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379–2386
   PubMed Web of Science ®Google Scholar
• Jeha S, Gaynon P S, Razzouk B I, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917–1923
   PubMed Web of Science ®Google Scholar
• Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 45–51
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940–947
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10
   PubMedGoogle Scholar
• Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363–365
   PubMed Web of Science ®Google Scholar
• Laszlo D, Galieni P, Raspadori D, et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 2000; 37: 157–161
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S, Sadus-Wojciechowska M, et al. Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients. Transplant Proc 2005; 37: 4482–4487
   PubMed Web of Science ®Google Scholar
• Nabhan C, Fried W, Galvez A, Venugopal P, Gozun P, Bitran J D. Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2008; 26: 8564, (abstr)
   Google Scholar
• Cunningham C, Nemunaitis J, Senzer N, Richards D, Vukelja S, Abidchandani R, et al. Effect of clofarabine on lymphocyte populations in patients treated for solid tumors. Proc Am Soc Clin Oncol 2007; 25: 21134, (abstr)
   Google Scholar
• Warrell R P, Jr., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Spriggs D R, Stopa E, Mayer R J, Schoene W, Kufe D W. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 1986; 46: 5953–5958
   PubMed Web of Science ®Google Scholar
• Cunningham C C, Nemunaitis J, Senzer N, Vukelja S, Richards D, Vukovic V, et al. Clofarabine administration weekly to adult patients with advanced solid tumors in a phase I dose-finding study. Proc Am Soc Clin Oncol 2005; 23: 7109, (abstr)
   Google Scholar
• Parker W B, Shaddix S C, Chang C H, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991; 51: 2386–2394
   PubMed Web of Science ®Google Scholar
• Xie K C, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl) adenine. Cancer Res 1996; 56: 3030–3037
   PubMed Web of Science ®Google Scholar
• Hegde U P, Wilson W H, White T, Cheson B D. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100: 2260–2262
   PubMed Web of Science ®Google Scholar
• Cheson B D, Vena D A, Foss F M, Sorensen J M. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12: 2216–2228
   PubMed Web of Science ®Google Scholar